Activating Killer-cell Immunoglobulin-like Receptors are associated with the severity of COVID-19

Etiopathogenesis of the clinical variability of the coronavirus disease 2019 (COVID-19) remains mostly unknown. Here we investigate the role of Killer-cell Immunoglobulin-like receptor (KIR)/Human Leukocyte Antigen Class-I (HLA-I) interactions in the susceptibility and severity of COVID-19. KIR and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infectious diseases 2021-04
Hauptverfasser: Bernal, Enrique, Gimeno, Lourdes, Alcaraz, María J, Quadeer, Ahmed A, Moreno, Marta, Martínez-Sánchez, María V, Campillo, José A, Gomez, Jose M, Pelaez, Ana, García, Elisa, Herranz, Maite, Hernández-Olivo, Marta, Martínez-Alfaro, Elisa, Alcaraz, Antonia, Muñoz, Ángeles, Cano, Alfredo, McKay, Matthew R, Muro, Manuel, Minguela, Alfredo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Etiopathogenesis of the clinical variability of the coronavirus disease 2019 (COVID-19) remains mostly unknown. Here we investigate the role of Killer-cell Immunoglobulin-like receptor (KIR)/Human Leukocyte Antigen Class-I (HLA-I) interactions in the susceptibility and severity of COVID-19. KIR and HLA-I genotyping and NK cell (NKc) receptors immunophenotyping in 201 symptomatic patients and 210 non-infected controls. NKcs with a distinctive immunophenotype, suggestive of recent activation (KIR2DS4 low CD16 low CD226 low CD56 high TIGIT high NKG2A high), expanded in patients with severe COVID-19. This was associated with a higher frequency of the functional A-telomeric activating KIR2DS4 in severe than mild/moderate patients and controls (83.7%, 55.7% and 36.2%, p
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiab228